Skip to main content
NCBI home page
Atencion Primaria logoLink to Atencion Primaria
. 2013 Apr 5;25(6):377–382. [Article in Spanish] doi: 10.1016/S0212-6567(00)78526-X

Beneficios del tratamiento erradicador de la infección por Helicobacter pylori en pacientes ulcerosos en un centro de atención primaria

Benefits of treatment to eradicate helicobacter pylori infection in patients with ulcers attending a primary care centre

R Azagra Ledesma a,*, E Gené Tous b, JM Bonet Simó b, F Solé Sancho b, X Calvet Calvo c
PMCID: PMC7675822  PMID: 10857226

Abstract

Objectives

To evaluate the clinical evolution and the use of Primary Care health resources one year after treatment to eradicate Helicobacter pylori (Hp) infection in patients with peptic ulcers and Hp infection.

Design

Retrospective study on the effect of an intervention.

Setting

Urban, reformed primary care centre.

Patients

102 patients with peptic ulcers and Hp infection.

Intervention

Treatment to eradicate Hp.

Measurements and main results

a) Total medical attendance; b) attendance for dyspepsia; c) number of ulcerous outbreaks; d) medicines taken to treat dyspepsia. 79.4% of the patients treated were male. Overall mean age was 47.8 ± 12.4. After the intervention, total attendance (from 8.3 to 6.6, p < 0.001), attendance for dyspepsia (from 3.1 to 1.1, p < 0.00001), and ulcerous outbreaks (from 1.2 to 0.06, p < 0.00001) all dropped sharply. The mean number of medicines prescribed for dyspepsia per patient fell from 1.24 to 0.43, p < 0.0001. Ranitidine prescription fell from 72.7 to 13.8 days (p < 0.001); and omeprazol from 35.1 to 12.2 days (p < 0.03). Estimated total saving per patient was 26792 pesetas at 1998 values.

Conclusions

Treatment in primary care to eradicate Hp (+) in ulcerous patients reduced the needs of attendance and the prescription of drugs for ulcers. Just in the first year this supposed a clinical benefit for these patients and important economic savings for the public health service.

Bibliografía

  • 1.Marshall B.J., Warren J.R. Unidentified curved bacili in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984;1:1311–1314. doi: 10.1016/s0140-6736(84)91816-6. [DOI] [PubMed] [Google Scholar]
  • 2.Marshall B.J. The Campylobacter pylori story. Scand J Gastroenterol. 1988;146(Supl):58–66. doi: 10.3109/00365528809099131. [DOI] [PubMed] [Google Scholar]
  • 3.Goodwin C.S., Armstrong J.A., Marshall B.J. Campylobacter pylori, gastritis, and peptic ulceration. J Clin Pathol. 1986;39:353–365. doi: 10.1136/jcp.39.4.353. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.DeCross A.J., Marshall B.J. The role of Helicobacter pylori in acid-peptic disease [see comments] Am J Med Sci. 1993;306:381–392. doi: 10.1097/00000441-199312000-00006. [DOI] [PubMed] [Google Scholar]
  • 5.Marshall B.J. The 1995 Albert Lasker Medical Research Award. Helicobacter pylori. The etiologic agent for peptic ulcer. JAMA. 1995;274:1064–1066. doi: 10.1001/jama.274.13.1064. [DOI] [PubMed] [Google Scholar]
  • 6.Borody T.J., Cole P., Noonan S., Morgan A., Lenne J., Hyland L. Recurrence of duodenal ulcer and Campylobacter pylori infection after eradication. Med J Aust. 1989;151:431–435. doi: 10.5694/j.1326-5377.1989.tb101251.x. [DOI] [PubMed] [Google Scholar]
  • 7.Van der Hulst R.W., Rauws E.A., Koycu B., Keller J.J., Bruno M.J., Tijssen J.G. Prevention of ulcer recurrence after eradication of Helicobacter pylori: a prospective long-term follow-up study. Gastroenterology. 1997;113:1082–1086. doi: 10.1053/gast.1997.v113.pm9322501. [DOI] [PubMed] [Google Scholar]
  • 8.Graham D.Y., Lew G.M., Klein P.D., Evans D.G., Evans D.J., Jr, Saeed Z.A. Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer.A randomized, controlled study. Ann Intern Med. 1992;116:705–708. doi: 10.7326/0003-4819-116-9-705. [DOI] [PubMed] [Google Scholar]
  • 9.NIH Consensus Conference Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. JAMA. 1994;272:65–69. [PubMed] [Google Scholar]
  • 10.Peterson W.L. Helicobacter pylori and peptic ulcer disease. N Engl J Med. 1991;324:1043–1048. doi: 10.1056/NEJM199104113241507. [DOI] [PubMed] [Google Scholar]
  • 11.Graham D.Y. Helicobacter pylori: its epidemiology and its role in duodenal ulcer disease. J Gastroenterol Hepatol. 1991;6:105–113. doi: 10.1111/j.1440-1746.1991.tb01448.x. [DOI] [PubMed] [Google Scholar]
  • 12.Sipponen P., Seppala K., Aarynen M., Helske T., Kettunen P. Chronic gastritis and gastroduodenal ulcer: a case control study on risk of coexisting duodenal or gastric ulcer in patients with gastritis. Gut. 1989;30:922–929. doi: 10.1136/gut.30.7.922. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Cullen D., Collins B.J., Christiansen K.J., Epis J., Warren J.R., Cullen K.J. Long term risk of peptic ulcer disease in people with Helicobacter pylori infection comunity based study. Gastroenterology. 1993;104 n.° 4 Part 2, A60. [Google Scholar]
  • 14.Marshall B.J., Goodwin C.S., Warren J.R., Murray R., Blincow E.D., Blackbourn S.J. Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet. 1988;2:1437–1442. doi: 10.1016/s0140-6736(88)90929-4. [DOI] [PubMed] [Google Scholar]
  • 15.Hentschel E., Brandstatter G., Dragosics B., Hirschl A.M., Nemec H., Schutze K. Effect of ranitidine and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer. N Engl J Med. 1993;328:308–312. doi: 10.1056/NEJM199302043280503. [DOI] [PubMed] [Google Scholar]
  • 16.Rauws E.A., Tytgat G.N. Cure of duodenal ulcer associated with eradication of Helicobacter pylori. Lancet. 1990;335:1233–1235. doi: 10.1016/0140-6736(90)91301-p. [DOI] [PubMed] [Google Scholar]
  • 17.Coghlan J.G., Gilligan D., Humphries H., McKenna D., Dooley C., Sweeney E. Campylobacter pylori and recurrence of duodenal ulcers-a 12-month follow-up study. Lancet. 1987;2:1109–1111. doi: 10.1016/s0140-6736(87)91545-5. [DOI] [PubMed] [Google Scholar]
  • 18.Forbes G.M., Glaser M.E., Cullen D.J., Warren J.R., Christiansen K.J., Marshall B.J. Duodenal ulcer treated with Helicobacter pylori eradication: seven-year follow-up. Lancet. 1994;343:258–260. doi: 10.1016/s0140-6736(94)91111-8. [DOI] [PubMed] [Google Scholar]
  • 19.Vakil N., Fennerty B. The economics of eradicating Helicobacter pylori infection in duodenal ulcer disease. Am J Med. 1996;100:60–63. doi: 10.1016/s0002-9343(96)80230-0. [DOI] [PubMed] [Google Scholar]
  • 20.O’Brien B., Goeree R., Mohamed A.H., Hunt R. Cost-effectiveness of Helicobacter pylori eradication for the long-term management of duodenal ulcer in Canada. Arch Intern Med. 1995;155:1958–1964. [PubMed] [Google Scholar]
  • 21.O’Brien B., Goeree R., Hunt R., Wilkinson J., Levine M., William A. Cost effectiveness of alternative Helicobacter pylori eradication strategies in the management of duodenal ulcer. Can J Gastroenterol. 1997;11:323–331. doi: 10.1155/1997/290183. [DOI] [PubMed] [Google Scholar]
  • 22.Sonnenberg A., Schwartz J.S., Cutler A.F., Vakil N., Bloom B.S. Cost savings in duodenal ulcer therapy through Helicobacter pylori eradication compared with conventional therapies: results of a randomized, double-blind, multicenter trial. Gastrointestinal Utilization Trial Study Group. Arch Intern Med. 1998;158:852–860. doi: 10.1001/archinte.158.8.852. [DOI] [PubMed] [Google Scholar]
  • 23.Ebell M.H., Warbasse L., Brenner C. Evaluation of the dyspeptic patient: a costutility study. J Fam Pract. 1997;44:545–555. [PubMed] [Google Scholar]
  • 24.Muñoz Gutiérrez J., Iglesias Franco H., García L. Fidalgo. Helicobacter pylori y patología gastroduodenal: patogenia, diagnóstico y pautas terapéuticas. Aten Primaria. 1997;19:377–382. [PubMed] [Google Scholar]
  • 25.Martínez-Sánchez G., Saperas E., Benavent J., Mearin F., Piñol J., Barenys M. Actitud de los médicos de atención primaria del área metropolitana de Barcelona frente al diagnóstico y tratamiento de la infección por Helicobacter pylori en enfermedades gastroduodenales. Gastroenterol Hepatol. 1998;21:473–478. [PubMed] [Google Scholar]
  • 26.Hirth R.A., Fendrick A.M., Chernew M.E. Specialist and generalist physicians’ adoption of antibiotic therapy to eradicate Helicobacter pylori infection. Med Care. 1996;34:1199–1204. doi: 10.1097/00005650-199612000-00005. [DOI] [PubMed] [Google Scholar]
  • 27.Fendrick A.M., Hirth R.A., Chernew M.E. Differences between generalist and specialist physicians regarding Helicobacter pylori and peptic ulcer disease. Am J Gastroenterol. 1996;91:1544–1548. [PubMed] [Google Scholar]
  • 28.Breuer T., Goodman K.J., Malaty H.M., Sudhop T., Graham D.Y. How do clinicians practicing in the U.S. manage Helicobacter pylori-related gastrointestinal diseases? A comparison of primary care and specialist physicians. Am J Gastroenterol. 1998;93:553–561. doi: 10.1111/j.1572-0241.1998.164_b.x. [DOI] [PubMed] [Google Scholar]
  • 29.Breuer T., Sudhop T., Goodman K.J., Graham D.Y., Malfertheiner P. How do practicing clinicians manage Helicobacter pylori-related gastrointestinal diseases in Germany? A survey of gastroenterologists and family practitioners. Helicobacter. 1998;3:1–8. doi: 10.1046/j.1523-5378.1998.08027.x. [DOI] [PubMed] [Google Scholar]
  • 30.European Society of Primary Care Gastroenterology The management of Helicobacter pylori infection. Guidance for the European Primary Care Physician. Bulletin. 1998 [Google Scholar]
  • 31.Chiba N., Rao B.V., Rademaker J.W., Hunt R.H. Meta-analysis of the efficacy of antibiotic therapy in eradicating Helicobacter pylori. Am J Gastroenterol. 1992;87:1716–1727. [PubMed] [Google Scholar]
  • 32.Gisbert J.P., Boixeda D., Martín de Argila C. Omeprazol y amoxicilina en el tratamiento erradicador de Helicobacter pylori. Rev Clin Esp. 1995;11:787–791. [PubMed] [Google Scholar]
  • 33.Jovell A., Aymerich M., García-Altés A., Serra-Prat M. Agència d’Avaluació de Tecnologia Mèdica Servei Català de la Salut Departament de Sanitat i Seguretat Social Generalitat de Catalunya; Barcelona:: septiembre 1998. Guía de práctica clínica del tratamiento erradicador de la infección por Helicobacter pylori asociada a úlcera duodenal en la atención primaria. [Google Scholar]
  • 34.Comet R., Calvet X., Navarro M., García N., Sanfeliu I. Omeprazol, claritromicina y amoxicilina durante 7 días para el tratamiento de la infección por Helicobacter pylori. Gastroenterol Hepatol. 1998;21:81–83. [PubMed] [Google Scholar]
  • 35.Calvet X. Tratamiento de la infección por Helicobacter pylori. Gastroenterol Hepatol. 1998;21:203–206. [PubMed] [Google Scholar]
  • 36.Inadomi J., Sonnenberg A. The impact of peptic ulcer disease and infection with Helicobacter pylori on life expectancy. Am J Gastroenterol. 1998;93:1286–1290. doi: 10.1111/j.1572-0241.1998.00410.x. [DOI] [PubMed] [Google Scholar]
  • 37.Ordre de 29 de setembre de 1997 per la qual s’aproven els preus públics corresponents als serveis que presta l’Institut Català de la Salut. Diari Oficial de la Generalitat de Catalunya. 1997;2.504:12149. [Google Scholar]
  • 38.JanéA A., Caldès M. Ciutat Badia: barri, ciutat i sistema metropolità. Barcelona: Direcció General d’Arquitectura i Habitatge, Departament de Política Territorial i Obres Públiques, Generalitat de Catalunya. 1985 [Google Scholar]
  • 39.Azagra R., Bonet J.M., Bravo M.L., Freixas M., Campanera M.T., Fuentes M. Seguimiento de la calidad de la prescripción de medicamentos: el CAP de Ciudad Badia (1986-1990) Aten Primaria. 1992;10:707–710. [PubMed] [Google Scholar]
  • 40.Labenz J., Malfertheiner P. Helicobacter pylori in gastro-oesophageal reflux disease: causal agent, independent or protective factor? Gut. 1997;41:277–280. doi: 10.1136/gut.41.3.277. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Guillen D., Wirz A.A., Ardill J.E., McColl E.L. Rebound hypersecretion after omeprazole and its relation to ontreatment acid suppression and Helicobacter pylori status. Gastroenterology. 1999;116:239–247. doi: 10.1016/s0016-5085(99)70118-6. [DOI] [PubMed] [Google Scholar]

Articles from Atencion Primaria are provided here courtesy of Elsevier

RESOURCES